Godavari Drugs Intrinsic Value
GODAVARI Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹107.80 | ₹86.24 - ₹129.36 | +24.9% | EPS: ₹4.90, Sector P/E: 22x |
| Book Value Method | asset | ₹107.50 | ₹96.75 - ₹118.25 | +24.6% | Book Value/Share: ₹53.75, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹172.58 | ₹155.32 - ₹189.84 | +100.0% | Revenue/Share: ₹132.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹134.44 | ₹121.00 - ₹147.88 | +55.8% | EBITDA: ₹11.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹186.77 | ₹149.42 - ₹224.12 | +116.4% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹31.36 | ₹28.22 - ₹34.50 | -63.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹69.85 | ₹62.86 - ₹76.83 | -19.1% | Revenue Growth: -9.9%, Adj P/E: 14.3x |
| ROE Based Valuation | profitability | ₹50.00 | ₹45.00 - ₹55.00 | -42.1% | ROE: 9.3%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹76.98 | ₹69.28 - ₹84.68 | -10.8% | EPS: ₹4.90, BVPS: ₹53.75 |
Want to compare with current market value? Check GODAVARI share price latest .
Valuation Comparison Chart
GODAVARI Intrinsic Value Analysis
What is the intrinsic value of GODAVARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Godavari Drugs (GODAVARI) is ₹107.50 (median value). With the current market price of ₹86.29, this represents a +24.6% variance from our estimated fair value.
The valuation range spans from ₹31.36 to ₹186.77, indicating ₹31.36 - ₹186.77.
Is GODAVARI undervalued or overvalued?
Based on our multi-method analysis, Godavari Drugs (GODAVARI) appears to be trading below calculated value by approximately 24.6%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.93 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 3.33 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 9.3% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.74x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Godavari Drugs
Additional stock information and data for GODAVARI
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹11 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹18 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹11 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |